Evidence map›Paper›PMID 41028262›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

In Vitro Coculture Model of Immune and Tumor Cells for Immunotherapy Studies of High Mutational Load Tumors.

Piroska Virág, Ioana Brie, Maria Perde-Schrepler

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Piroska VirágThe Oncology Institute "Prof. Dr. I. Chiricuţă" Cluj-Napoca, Cluj-Napoca, Romania. virag.piroska@iocn.ro.
Ioana BrieThe Oncology Institute "Prof. Dr. I. Chiricuţă" Cluj-Napoca, Cluj-Napoca, Romania.
Maria Perde-SchreplerThe Oncology Institute "Prof. Dr. I. Chiricuţă" Cluj-Napoca, Cluj-Napoca, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To obtain a better tumor cell killing mediated by cytotoxic T lymphocytes (CTLs), several strategies were developed that might prime tumor-specific T-cell responses. One such strategy is combining the immune checkpoint inhibitors (CPI) blockade with radiotherapy (RT), considering the synergy between these two types of therapies. Here, we present an in vitro experimental model of cocultures of human tumor cell lines (A549 lung carcinoma and SK-Mel-1 melanoma) and immune cells (CTLs), in which CTLs activation is attempted by irradiation of the tumor cells with ionizing radiations and by the treatment of CTLs with an anti-programmed death-1 (anti-PD-1) drug. This model is suitable for studying cellular death, inflammatory responses, molecule expression, and immunotherapy.

Indexed as

ImmunotherapyMutationNeoplasmsT-Lymphocytes, CytotoxicA549 CellsCell Line, TumorCoculture TechniquesHumansImmune Checkpoint InhibitorsLymphocyte ActivationImmune Checkpoint InhibitorsCellular deathCoculturesCytotoxicityHigh mutational load tumorsImmune checkpoint inhibitorsImmunogenicityImmunotherapyInflammatory responsesProgrammed cell death protein

Identifiers

PMID41028262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.